Nasopharyngeal Carcinoma Trial Landscape (May 2026)

Last updated: May 13, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

215
Recruiting
17
Phase 1
101
Phase 2
82
Phase 3
2
Phase 4

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Checkpoint inhibitor
70
Antibody-drug conjugate (ADC)
8
Chemotherapy
7
Bispecific antibody
6
Other / unclassified
5
Monoclonal antibody
3
Other inhibitor
2
Small-molecule inhibitor
1
Tyrosine kinase inhibitor (TKI)
1
Vaccine (other)
1
CAR-T cellular therapy
1
Hormonal / nuclear-receptor therapy
1

Recently Updated Trials

NCTPhaseTitleMechanism
NCT063232392SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal CarcinomaPD-1 -- immune checkpoint inhibitor (monoclonal antibody)
NCT053404913Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialPD-1 -- immune checkpoint inhibitor (monoclonal antibody)
NCT059417413IC Plus Low-dose Radiation Plus Cadonilimab in LANPCPD-1 + CTLA-4 + low-dose radiation -- immune checkpoint inhibitors + radiotherapy
NCT068028351, 2EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma—
NCT07578727—Photon Intensity-modulated Radiotherapy for Nasopharyngeal CarcinomaUnknown mechanism

Top Sponsors

SponsorRecruiting trials
Sun Yat-sen University77
Fujian Cancer Hospital9
Jiangxi Provincial Cancer Hospital8
Fudan University8
Zhejiang Cancer Hospital6

Geographic Distribution

Countries with the most active trial sites for nasopharyngeal carcinoma. A multi-site trial is counted once per country.

China
152
United States
14
Singapore
9
Canada
4
South Korea
3
Italy
3
Australia
3
Spain
2
Hong Kong
2
Germany
2

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

StartNCTTitleMechanism
Mar 31, 2026NCT07320963Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.HDAC + PD-1 + VEGFR -- HDAC inhibitor + immune checkpoint inhibitor + multi-kinase inhibitor

Want trials matched to a specific patient profile?

Enter biomarkers, stage, and prior treatments — get ranked trial matches with eligibility breakdown in minutes.

Find Matching Trials

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.